-
Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization
In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing…
-
New Breakthrough in Fixed-Duration Regimens: PVR Regimen Reduces Risk of Progression by 45% Compared to VR in R/R CLL Patients
At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab…
-
52% Reduction in Risk of Progression! Phase III SUCCESSOR-2 Trial Confirms Superior Efficacy of MeziKd in RRMM Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Meletios Dimopoulos from the National and Kapodistrian University of Athens was invited to deliver a presentation titled “Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial.”
-
Deep Remission and Long-term Benefit: MAJESTEC-4 Study Reveals the Remarkable Potential of Teclistamab ± Lenalidomide as Post-transplant Maintenance Therapy for NDMM
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Niels van de Donk from the Amsterdam University Medical Center (Amsterdam UMC), representing the EMN30 study group, announced the updated safety run-in (SRI) results of the EMN30/MAJESTEC-4 study. This study aims to evaluate the safety and preliminary efficacy of the BCMA×CD3 bispecific antibody Teclistamab (Tec),…
-
Towards Clinical Cure? ImmunoPRISM Study Confirms 82% MRD Negativity Rate with Teclistamab in HRSMM
At the EHA 2026 conference, Professor Omar Nadeem from the Dana-Farber Cancer Institute (USA) announced the latest results of the Phase II ImmunoPRISM trial. This study compared the BCMA×CD3 bispecific antibody Teclistamab with the standard regimen of lenalidomide + dexamethasone (Rd) in patients with high-risk smoldering multiple myeloma (HRSMM), providing heavy evidence for early precision…
-
Science Without Borders, Moving Towards a “Cure”: In-depth Report on the 2026 EHA Opening Ceremony—Focusing on MPN Disease Modification and New Breakthroughs in Immunotherapy for Multiple Myeloma
In June 2026, the world-renowned European Hematology Association (EHA) Annual Congress grandly opened in Stockholm, Sweden. As one of the largest and most influential academic events in the global field of hematology, this year’s EHA Congress not only brought together top-tier academic research results but also defined the development direction for global hematology diagnosis and…
-
Risk Reduced by 72%! MONUMENTAL-3 Study Confirms GPRC5D Bispecific Antibody Combinations Open a New Era of Precision Treatment for RRMM
At the recent European Hematology Association (EHA) Annual Congress, Professor Peter Voorhees from the Atrium Health Levine Cancer Institute (Charlotte, USA) was invited to share the preliminary results of the MONUMENTAL-3 study (NCT05455320). This study is the first randomized Phase 3 clinical trial evaluating GPRC5D-targeted therapy in combination with Daratumumab ± Pomalidomide for the treatment…
-
Crossing the Boundary Between Medicine and Reality: EMN Chairman Pieter Sonneveld’s In-depth Analysis of Immunotherapy Innovation and Reimbursement Dilemmas in Multiple Myeloma
The treatment landscape for multiple myeloma (MM) has undergone revolutionary changes over the past two decades, transitioning from the traditional chemotherapy era to a golden age of precision targeting and immunotherapy. However, does immense success in clinical evidence translate to broad benefits for patients? At the 29th Annual Congress of the European Hematology Association (EHA),…
Connecting Medical Expertise through Media